Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2019Experimental and Therapeutic MedicineOpen Access

Aminoguanidine reduces diabetes‑associated cardiac fibrosis

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The molecular mechanism by which aminoguanidine reduces advanced glycation end product-associated damage in diabetes is not well understood.

Population

Forty-five male Wistar rats and primary rat myofibroblasts

Comparison

T2DM treated with aminoguanidine vs untreated T2DM and control

Design

Preclinical animal and in vitro study

Follow-up

Up to 25 weeks

Authors

FMFernando MagdalenoCBChuck BlajszczakCCClaudia Charles‐Ni�o

Discussion

Loading...

Member takes

Overview

AG mitigates cardiac fibrosis in T2DM rats; leaves open human translation and requires clinical trials.

Structured PICO

P
Population
45 male Wistar rats with type 2 diabetes mellitus induced by high-fat, high-carbohydrate diet and low-dose streptozotocin (20 mg/kg), and primary rat myofibroblasts.
I
Intervention
Aminoguanidine (AG) 20 mg/kg for up to 25 weeks (in vivo) and AG treatment (in vitro).
C
Comparator
Control rats and untreated T2DM rats.
O
Outcome
Cardiac fibrosis and expression of α-smooth muscle actin (αSMA), Nox4, and Nos2 mRNA.surrogate

Aminoguanidine reduces oxidative stress-associated cardiac fibrosis in a diabetic rat model by modulating AGE/RAGE signaling and downstream fibrogenic pathways.

Cite This Study

Magdaleno et al. (2019) studied this question.

synapsesocial.com/papers/6a70553ef44fa9f079ddf264https://doi.org/10.3892/etm.2019.7921
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin‐induced diabetes in rats2006 · 35 citations
  2. 2Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes2006 · 40 citations
  3. 3Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-22022 · 6 citations
  4. 4Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide‐induced type 2 diabetes2008 · 29 citations
  5. 52-Arachidonoylglycerol Attenuates Myocardial Fibrosis in Diabetic Mice Via the TGF-β1/Smad Pathway2022 · 9 citations